N=1 Medicine

Where AI meets multi-omics, we begin to understand each tumor as a unique ecosystem

Rewriting the future of cancer care

DAiNA has built and is constantly expanding a global ecosystem that enables the design, development, and GMP-compliant manufacturing of individualized cancer therapies. Acting as an intermediary platform, DAiNA connects clinical oncology teams, biotechnology innovators, manufacturing partners, and regulatory stakeholders to translate molecular insights into personalized therapeutic interventions.
Through its partner network, DAiNA provides end-to-end orchestration of individualized therapeutic programs, from molecular profiling and therapeutic design to Good Manufacturing Practice (GMP) production and clinical application. By coordinating all stakeholders within a structured framework, DAiNA enables the efficient development and delivery of highly personalized therapies for individual patients.
DAiNA's ecosystem currently supports four primary categories of precision oncology interventions:

Repurposing Approved Drugs for Off-Label Use

Personalized Cancer Vaccines

Personalized Nucleic Acid Therapeutics

Liquid Biopsy / Personalized ctDNA Monitoring

Personalized Solid Tumor CAR-T Development

Coordinating the N=1 Medicine Ecosystem

The design and production of individualized therapies (n=1 medicines) require the complex and successful interaction of multiple stakeholders, including the patient, the treating clinical oncology team, manufacturing partners operating under GMP standards, and the relevant regulatory authorities.
Such programs must operate within rigorous ethical standards and applicable regulatory frameworks governing individualized and investigational therapies.
DAiNA manages and coordinates this multi-stakeholder process on behalf of its partners and clients. The platform ensures that therapeutic design, manufacturing, documentation, and clinical implementation comply with applicable United States, European Union, and Swiss regulatory requirements, as well as internationally recognized Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards.
By orchestrating this ecosystem, DAiNA enables the safe, compliant, and scalable development of personalized therapies, ensuring alignment between scientific innovation, regulatory oversight, and patient care.